Cresset Asset Management »

Halozyme Therapeutics shares owned by Cresset Asset Management

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by Cresset Asset Management from 13F filings

Historical chart of Cresset Asset Management investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Cresset Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Cresset Asset Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $11M 281k 40.68
2023-12-31 $7.7M 208k 36.96
2023-09-30 $6.9M 180k 38.20
2023-06-30 $3.8M 106k 36.07

More positions owned by Cresset Asset Management

Arista Networks Put Option (ANET)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Ishares Tr Core S&p500 Etf (IVV)
Ishares Tr Core S&p Scp Etf (IJR)
Ishares Tr S&p 100 Etf (OEF)
Invesco Exchange Traded Fd T S&p500 Eql Wgt (RSP)
Apple (AAPL)
Microsoft Corporation (MSFT)
Meta Platforms Cl A Put Option (META)
Ishares Tr Core Msci Eafe (IEFA)
Vanguard Intl Equity Index F Allwrld Ex Us (VEU)
Alphabet Cap Stk Cl A (GOOGL)
Amazon (AMZN)
NVIDIA Corporation Put Option (NVDA)
Vanguard Index Fds Total Stk Mkt (VTI)

View all positions for Cresset Asset Management

Top funds holding Halozyme Therapeutics

BlackRock
Vanguard Group
State Street Corporation
Snyder Capital Management
Artisan Partners Limited Partnership
Alliancebernstein
Macquarie Group
Jpmorgan Chase & Co
Geode Capital Management
TD Asset Management
Invesco
Jennifer Ranahan
Arrowpoint Asset Management
Dimensional Fund Advisors
Bank of America Corporation

View all funds holding Halozyme Therapeutics